Fair value · Telix Pharmaceuticals Ltd (TLX) · updated 2026-08-28 · from annual report FY2025
Three independent valuation methods run on Telix Pharmaceuticals’s own SEC filings. Three say overvalued. The spread is wide, so treat it as a rough guide.
Prices and market caps: Cboe delayed data, at least 15 minutes delayed. Not real-time. Fundamentals from SEC filings.
Bear, base and bull are the 25th, 50th and 75th percentile of the methods that produced a usable estimate. Weights say how much a method is trusted for this sector; they do not change the range.
| Method | Estimate | vs price | Weight | Why this method |
|---|---|---|---|---|
EV/EBITDA Medium weight Values the whole business at 10× EBITDA and divides by the share count. A mid-cycle industrial multiple; fast growers trade far above it. | $0.48 | -96% | Medium weight | Values the whole business at 10× EBITDA and divides by the share count. A mid-cycle industrial multiple; fast growers trade far above it. |
Earnings Power Value Medium weight Greenwald’s Earnings Power Value: what current earnings are worth if they never grow. Everything above it is what you pay for growth. | $0.76 | -93% | Medium weight | Greenwald’s Earnings Power Value: what current earnings are worth if they never grow. Everything above it is what you pay for growth. |
annual report FY2025 · fiscal year ended 2025-12-31 · filed 2026-02-20 · accession 0001628280-26-009943
Open this filing on sec.govDCF High weight Projects free cash flow for the coming years and discounts it back to today. The most complete method, and the most sensitive to the growth and discount-rate assumptions. | $4.14 | -64% | High weight | Projects free cash flow for the coming years and discounts it back to today. The most complete method, and the most sensitive to the growth and discount-rate assumptions. |
P/E vs sector Medium weight Trailing diluted EPS times the sector median P/E. What the stock would be worth if the market priced it like an average peer. Negative or unavailable EPS | No estimate | Medium weight | Trailing diluted EPS times the sector median P/E. What the stock would be worth if the market priced it like an average peer. | |
Growth-trajectory DCF Medium weight A two-stage DCF that grows earnings at the company’s own EPS trend, then fades to the industry’s long-run rate. No trajectory data available | No estimate | Medium weight | A two-stage DCF that grows earnings at the company’s own EPS trend, then fades to the industry’s long-run rate. | |
P/B vs sector Medium weight Sector median price-to-book times book value per share. Works for banks and asset-heavy businesses, says little about software. Sector P/B benchmark unavailable | No estimate | Medium weight | Sector median price-to-book times book value per share. Works for banks and asset-heavy businesses, says little about software. | |
Graham Number Medium weight Benjamin Graham’s 1949 rule of thumb: √(22.5 × EPS × book value). It punishes asset-light companies, so it reads low for big tech. Requires positive EPS | No estimate | Medium weight | Benjamin Graham’s 1949 rule of thumb: √(22.5 × EPS × book value). It punishes asset-light companies, so it reads low for big tech. | |
EV/FCF Medium weight 20× free cash flow per share, i.e. a 5% cash yield. Reads low for companies the market expects to keep growing. Negative FCF — common for growth companies; ratio not meaningful | No estimate | Medium weight | 20× free cash flow per share, i.e. a 5% cash yield. Reads low for companies the market expects to keep growing. | |
PEG Ratio is not meaningful: Insufficient price/EPS data
Interpretation
PEG = P/E ÷ Annual EPS Growth Rate (%). Peter Lynch's growth-adjusted value metric.
Interpretation
EV/EBITDA = Enterprise Value ÷ EBITDA. Capital-structure neutral — preferred by professional investors.
Interpretation
P/S = Market Cap ÷ Revenue. Useful for growth/unprofitable companies. SaaS/high-growth norms higher.
Excludes goodwill & intangibles — useful when acquisitions inflate book value.
Interpretation
P/B = Price ÷ Book Value per Share. Essential for banks, REITs, and asset-heavy companies.
Graham Number is not meaningful: Negative or zero EPS — Graham Number not meaningful
Interpretation
√(22.5 × EPS × Book Value/Share) — Benjamin Graham's intrinsic value estimate.
-93.3% vs current price ($11.38)
🔴 Destroying value
Greenwald EPV assumes zero future growth — this is the floor value of the business as a going concern.
Two of the seven methods, each with its own assumptions you can change. The fair-value range at the top of the page blends all seven; the numbers below will differ from it by design.
Download the full TLX valuation report (PDF) — free
DCF fair value, Graham number, EPV, key multiples and growth rates in one clean PDF.
